INCY Incyte Corp

Price (delayed)

$69.26

Market cap

$15.3B

P/E Ratio

44.97

Dividend/share

N/A

EPS

$1.54

Enterprise value

$13.53B

Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware. The company was founded in Palo Alto, California in 1991 and went public in 1993. Incyte has one drug, ...

Highlights
The debt is down by 34% year-on-year
INCY's equity is up by 25% year-on-year and by 8% since the previous quarter
INCY's EPS is down by 30% QoQ
INCY's net income is down by 29% since the previous quarter

Key stats

What are the main financial stats of INCY
Market
Shares outstanding
220.84M
Market cap
$15.3B
Enterprise value
$13.53B
Valuations
Price to earnings (P/E)
44.97
Price to book (P/B)
5.19
Price to sales (P/S)
5.6
EV/EBIT
33.22
EV/EBITDA
29.31
EV/Sales
4.97
Earnings
Revenue
$2.72B
EBIT
$407.24M
EBITDA
$461.65M
Free cash flow
$449.83M
Per share
EPS
$1.54
Free cash flow per share
$2.04
Book value per share
$13.35
Revenue per share
$12.36
TBVPS
$16.3
Balance sheet
Total assets
$3.9B
Total liabilities
$968.76M
Debt
$34.25M
Equity
$2.94B
Working capital
$1.96B
Liquidity
Debt to equity
0.01
Current ratio
3.97
Quick ratio
3.82
Net debt/EBITDA
-3.82
Margins
EBITDA margin
17%
Gross margin
94.9%
Net margin
12.4%
Operating margin
15.8%
Efficiency
Return on assets
9.4%
Return on equity
12.7%
Return on invested capital
38.1%
Return on capital employed
12.6%
Return on sales
15%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

INCY stock price

How has the Incyte stock price performed over time
Intraday
0.38%
1 week
-8.76%
1 month
-8.48%
1 year
-19.98%
YTD
-20.37%
QTD
-17.68%

Financial performance

How have Incyte's revenue and profit performed over time
Revenue
$2.72B
Gross profit
$2.58B
Operating income
$430.05M
Net income
$337.64M
Gross margin
94.9%
Net margin
12.4%
The net margin is down by 30% since the previous quarter
INCY's net income is down by 29% since the previous quarter
INCY's operating margin is down by 18% since the previous quarter
Incyte's operating income has decreased by 18% from the previous quarter

Growth

What is Incyte's growth rate over time

Valuation

What is Incyte stock price valuation
P/E
44.97
P/B
5.19
P/S
5.6
EV/EBIT
33.22
EV/EBITDA
29.31
EV/Sales
4.97
INCY's EPS is down by 30% QoQ
The stock's price to book (P/B) is 63% less than its 5-year quarterly average of 14.1 and 27% less than its last 4 quarters average of 7.1
INCY's equity is up by 25% year-on-year and by 8% since the previous quarter
INCY's P/S is 49% below its 5-year quarterly average of 11.0 and 21% below its last 4 quarters average of 7.1
Incyte's revenue has increased by 14% YoY

Efficiency

How efficient is Incyte business performance
The ROE has contracted by 33% from the previous quarter
INCY's return on assets is down by 32% since the previous quarter
The ROIC has decreased by 27% from the previous quarter
INCY's ROS is down by 25% QoQ

Dividends

What is INCY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INCY.

Financial health

How did Incyte financials performed over time
Incyte's total assets has increased by 22% YoY and by 7% from the previous quarter
INCY's total liabilities is up by 12% year-on-year and by 3.8% since the previous quarter
The debt is 99% smaller than the equity
The debt to equity has plunged by 50% YoY
The debt is down by 34% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.